Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Phase II Trial of VP-16, Bleomycin, and Cisplatin in Patients with Advanced Nonsquamous Cell Head and Neck Neoplasms

Creagan, Edward T., M.D.; Schutt, Allan J., M.D.; Richardson, Ronald L., M.D.; Schaid, Daniel J., Ph.D.

American Journal of Clinical Oncology: August 1993 - Volume 16 - Issue 4 - p 293–294
Original Article: PDF Only

We observed a 45% response rate from the combination of VP-16, bleomycin, and cisplatin among 20 patients with nonsquamous cell head and neck cancer. The regressions were partial and typically occurred within 1 to 2 months of commencing treatment. The median response duration for responding patients was 3 months. Median survival of responders was 8 months, similar to that of all study participants. Gastrointestinal and hematologic sequelae were predictable and manageable. This regimen may provide some transient palliation for selected patients with these neoplasms, but no substantive impact on survival.

Division of Medical Oncology (E.T.C., A.J.S., R.L.R.) and Cancer Center Statistics (D.J.S.), Mayo Clinic, Rochester, Minnesota, U.S.A.

© Lippincott-Raven Publishers.